Publication

Article

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

ON FEBRUARY 3, 2024, a select multidisciplinary group of physicians that included surgeons, radiation oncologists, and medical oncologists from academic and community practices participated in a live workshop to discuss current practices and recent updates on ADCs for the treatment of patients with NSCLC. A discussion moderated by Ticiana Leal, MD, provided perspectives and insights on approved and emerging ADCs in NSCLC including key clinical trial data on ADC efficacy and safety, treatment selection, and strategies to manage associated adverse events (AEs). Leal also presented patient cases for discussion.

Download PDF
Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Related Content
Antonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology
July 26th 2024

CHMP Recommends Amivantamab Plus Chemo for Pretreated EGFR+ Advanced NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Jonathan W. Riess, MD, MS
July 26th 2024

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

ODAC Votes to Require Within Trial Assessment of Neoadjuvant vs Adjuvant Treatment Benefit in Perioperative Trial Protocols in Resectable NSCLC
July 25th 2024

ODAC Votes to Require Within Trial Assessment of Neoadjuvant vs Adjuvant Treatment Benefit in Perioperative Trial Protocols in Resectable NSCLC

Lisa Conte
July 23rd 2024

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy